SG Americas Securities LLC Buys Shares of 11,941 Sight Sciences, Inc. (NASDAQ:SGHT)

SG Americas Securities LLC bought a new position in Sight Sciences, Inc. (NASDAQ:SGHT) in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 11,941 shares of the company’s stock, valued at approximately $75,000.

Several other hedge funds have also recently modified their holdings of SGHT. State Board of Administration of Florida Retirement System bought a new position in Sight Sciences during the first quarter valued at approximately $59,000. Steele Capital Management Inc. bought a new position in shares of Sight Sciences during the 2nd quarter valued at $67,000. The Manufacturers Life Insurance Company purchased a new position in shares of Sight Sciences in the 2nd quarter worth $95,000. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Sight Sciences by 51.9% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 26,653 shares of the company’s stock worth $141,000 after acquiring an additional 9,106 shares during the period. Finally, American Century Companies Inc. increased its position in Sight Sciences by 31.1% during the second quarter. American Century Companies Inc. now owns 35,948 shares of the company’s stock valued at $240,000 after acquiring an additional 8,527 shares during the last quarter. Hedge funds and other institutional investors own 55.51% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on SGHT. Needham & Company LLC restated a “hold” rating on shares of Sight Sciences in a research note on Friday, August 2nd. Citigroup upped their target price on shares of Sight Sciences from $6.00 to $6.50 and gave the company a “neutral” rating in a report on Wednesday, July 10th. Morgan Stanley lifted their price target on shares of Sight Sciences from $5.40 to $6.50 and gave the stock an “equal weight” rating in a research note on Monday, July 15th. Finally, Lake Street Capital initiated coverage on shares of Sight Sciences in a research report on Wednesday, August 21st. They set a “buy” rating and a $10.00 price objective for the company. Four analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $7.25.

Sight Sciences Trading Up 3.7 %

Shares of NASDAQ:SGHT opened at $5.39 on Tuesday. Sight Sciences, Inc. has a 12-month low of $1.13 and a 12-month high of $8.45. The company has a market cap of $271.17 million, a PE ratio of -5.04 and a beta of 2.71. The stock has a 50 day moving average of $6.24 and a 200 day moving average of $6.28. The company has a current ratio of 11.01, a quick ratio of 10.50 and a debt-to-equity ratio of 0.33.

Sight Sciences (NASDAQ:SGHT) last posted its quarterly earnings results on Thursday, August 1st. The company reported ($0.25) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.06. Sight Sciences had a negative net margin of 65.90% and a negative return on equity of 45.68%. The business had revenue of $21.37 million during the quarter, compared to analyst estimates of $21.32 million. During the same period in the prior year, the business posted ($0.30) earnings per share. As a group, equities research analysts expect that Sight Sciences, Inc. will post -1 EPS for the current year.

Insiders Place Their Bets

In other news, CFO Alison Bauerlein sold 10,130 shares of the business’s stock in a transaction dated Tuesday, October 1st. The stock was sold at an average price of $6.08, for a total value of $61,590.40. Following the transaction, the chief financial officer now directly owns 392,555 shares in the company, valued at $2,386,734.40. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, insider Matthew Link sold 21,831 shares of the company’s stock in a transaction on Monday, October 21st. The shares were sold at an average price of $5.61, for a total transaction of $122,471.91. Following the completion of the transaction, the insider now owns 663,550 shares in the company, valued at approximately $3,722,515.50. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Alison Bauerlein sold 10,130 shares of Sight Sciences stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $6.08, for a total transaction of $61,590.40. Following the completion of the sale, the chief financial officer now owns 392,555 shares in the company, valued at approximately $2,386,734.40. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 97,357 shares of company stock worth $574,666. Corporate insiders own 28.90% of the company’s stock.

About Sight Sciences

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.